Latest Breaking News On - Editing medicine targeting - Page 1 : vimarsana.com

Verve Therapeutics (VERV) Reports New Preclinical Data Demonstrating Potent and Durable Editing of ANGPTL3 Gene with VERVE-201

Verve Therapeutics (VERV) Reports New Preclinical Data Demonstrating Potent and Durable Editing of ANGPTL3 Gene with VERVE-201
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Jen robinsonAshlea kosikowskiAndrew bellingerExchange commissionEditing medicine targetingErnestn morial convention centerVerve therapeutics incPreclinical data supporting potential efficacyPrimary human cellsHighlighted original researchIschemic heart diseaseConvention centerPrivate securities litigation reform act

Verve Therapeutics Reports New Preclinical Data Demonstrating Potent and Durable Editing of ANGPTL3 Gene with VERVE-201 in Wild-type and LDLR-deficient Non-Human Primates

VERVE-201 Preclinical Data Supports Advancement of Drug Candidate Toward Clinical Development for Homozygous Familial Hypercholesterolemia, with Initiation of Clinical Trial Anticipated in 2024 Data. | March 3, 2023

United statesJen robinsonAndrew bellingerExchange commissionEditing medicine targetingClinical development for homozygous familial hypercholesterolemiaErnestn morial convention centerVerve therapeutics incData supports advancementDrug candidate toward clinical developmentHomozygous familial hypercholesterolemiaClinical trial anticipatedPresented duringOral presentationAnnual scientific sessionsPreclinical data supporting potential efficacy